Berlin Cures was first to follow up on the scientific finding that there are a large number of diseases associated with pathological functional autoantibodies directed against G protein-couples receptors. Heart failure and Long Covid belong to this group of diseases. Our aptamer BC 007 can neutralize these autoantibodies and this is the reason why Berlin Cures has been working for decades to develop a product based on scientific findings that may help many suffering patients.
Company Details
- Employees
- 10
- Founded
- -
- Address
- Grienbachstr. 11, Zug,zug 6300,switzerland
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- berlincures.de
- Keywords
- Aptamers and Autoantibodies.
- HQ
- Zug, Zug
Berlin Cures Holding Ag Questions
Berlin Cures Holding Ag's website is berlincures.de
Berlin Cures Holding Ag's LinkedIn profile is https://ch.linkedin.com/company/berlin-cures-holding-ag
Berlin Cures Holding Ag has
10 employees.
View email and phone details for 10
employees at Berlin Cures Holding Ag.
Berlin Cures Holding Ag's industry is
Pharmaceutical Manufacturing
Berlin Cures Holding Ag's top competitors are
Captain T Cell,
Mitodicure Gmbh,
Polpharma Biologics,
Aprofol Ag,
Omeicos Therapeutics Gmbh,
Neutrogen Therapeutics,
Berlin Heals Holding Ag,
Minerva Partners Ag,
Aptarion Biotech Ag,
Immuneadvice Gmbh.
Berlin Cures Holding Ag's categories are Pharmaceutical Manufacturing
Berlin Cures Holding Ag's founding year is 2014
